{"protocolSection":{"identificationModule":{"nctId":"NCT01347580","orgStudyIdInfo":{"id":"D5130L00006"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)","officialTitle":"A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.","acronym":"ATLANTIC"},"statusModule":{"statusVerifiedDate":"2015-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-09"},"primaryCompletionDateStruct":{"date":"2013-11","type":"ACTUAL"},"completionDateStruct":{"date":"2013-11","type":"ACTUAL"},"studyFirstSubmitDate":"2011-04-19","studyFirstSubmitQcDate":"2011-05-03","studyFirstPostDateStruct":{"date":"2011-05-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-11-13","resultsFirstSubmitQcDate":"2015-01-26","resultsFirstPostDateStruct":{"date":"2015-02-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-07-20","lastUpdatePostDateStruct":{"date":"2015-07-22","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.\n\nThe study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms:\n\nre-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.\n\nor In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.\n\nPatients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI.\n\nAfter the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation."},"conditionsModule":{"conditions":["Myocardial Infarction","Segment Elevation Myocardial Infarction (STEMI)"],"keywords":["Heart attack","heart disease","cardiovascular disease","stroke","reperfusion","pre hospital settings","ticagrelor","Percutaneous Coronary Intervention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1875,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Ticagrelor","type":"EXPERIMENTAL","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.","interventionNames":["Drug: Ticagrelor"]},{"label":"Placebo","type":"EXPERIMENTAL","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Ticagrelor","description":"Oral Ticagrelor loading dose (180 mg) followed by matching placebo","armGroupLabels":["Ticagrelor"]},{"type":"DRUG","name":"Placebo","description":"Placebo followed by oral Ticagrelor loading dose (180 mg)","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)","description":"(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.","timeFrame":"At initial angiography, pre PCI"},{"measure":"ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)","description":"ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\\<70%) resolution.","timeFrame":"Between baseline and PCI"}],"secondaryOutcomes":[{"measure":"1st Composite Clinical Endpoint","description":"death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death","timeFrame":"during the 30 days of treatment"},{"measure":"2nd Composite Clinical Endpoint","description":"Death/MI/urgent revascularization. Adjudicated events except death","timeFrame":"within 30 days of study"},{"measure":"Definite Stent Thrombosis","description":"Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint","timeFrame":"during 30 days of treatment"},{"measure":"TIMI Flow Grade 3 Post -PCI","description":"TIMI) flow grade 3 is complete perfusion post-PCI.","timeFrame":"at coroangiography post-PCI"},{"measure":"ST Segment Elevation Resolution Post-PCI >= 70%","description":"ST segment elevation resolution post PCI \\>=70% is defined as complete resolution","timeFrame":"Between baseline and ECG 60 mn post-PCI"},{"measure":"Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI","description":"Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.","timeFrame":"during PCI"},{"measure":"Major Bleeds Within 48 Hours","description":"non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds","timeFrame":"within 48 hours of first dose"},{"measure":"Minor and Major Bleedings Within 48 Hours","description":"non CABG related bleeds (PLATO definition)","timeFrame":"within 48 hours of first dose"},{"measure":"Major Bleeds After 48 Hours","description":"non CABG related bleeds (PLATO definition) include life threatening and other major bleedings","timeFrame":"after 48hours post-first dose"},{"measure":"Minor and Major Bleeds After 48 Hours","description":"non CABG related bleeds (PLATO definition)","timeFrame":"after 48 hours post first dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women must not be of child-bearing potential (1 year post-menopausal or surgically sterile).\n* Symptoms of acute MI of more than 30 min but less than 6 hours\n* New persistent ST-segment elevation ≥ 1 mm in two or more contiguous electrocardiogram (ECG) leads.\n\nExclusion Criteria:\n\n* Expected time to 1st PCI balloon inflation in the hospital, from the qualifying ECG is more than 120 minutes\n* Contraindication to ticagrelor (refer to SmPC)\n* Concomitant medication that may increase the risk of bleeding \\[e.g non steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulant and / or fibrinolytics, planned or administered 24 hours before randomization\\]\n* Any of the following conditions in the absence of a functioning implanted pacemaker: known SSS, second or third degree AVB, or documented syncope of suspected bradycardic origin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dr Judith Hsia, MD","affiliation":"AstraZeneca","role":"STUDY_DIRECTOR"},{"name":"Pr Gilles Montalescot","affiliation":"Pitie Salpetriere Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Algiers","country":"Algeria","geoPoint":{"lat":36.73225,"lon":3.08746}},{"facility":"Research Site","city":"Blida","country":"Algeria","geoPoint":{"lat":36.47004,"lon":2.8277}},{"facility":"Research Site","city":"Herston","country":"Australia","geoPoint":{"lat":-27.44453,"lon":153.01852}},{"facility":"Research Site","city":"Southport","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Research Site","city":"Woolloongabba","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Research Site","city":"Graz","country":"Austria","geoPoint":{"lat":47.06667,"lon":15.45}},{"facility":"Research Site","city":"Innsbruck","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Research Site","city":"Wien","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Halifax","state":"Nova Scotia","country":"Canada","geoPoint":{"lat":44.64533,"lon":-63.57239}},{"facility":"Research Site","city":"Newmarket","state":"Ontario","country":"Canada","geoPoint":{"lat":44.05011,"lon":-79.46631}},{"facility":"Research Site","city":"Scarborough","state":"Ontario","country":"Canada","geoPoint":{"lat":43.77223,"lon":-79.25666}},{"facility":"Research Site","city":"Regina","state":"Saskatchewan","country":"Canada","geoPoint":{"lat":50.45008,"lon":-104.6178}},{"facility":"Research Site","city":"Aalborg","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Research Site","city":"Odense C","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Research Site","city":"Århus","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}},{"facility":"Research Site","city":"Aubervilliers","country":"France","geoPoint":{"lat":48.91667,"lon":2.38333}},{"facility":"Research Site","city":"Besançon","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"Research Site","city":"Boulogne Billancourt","country":"France","geoPoint":{"lat":48.83333,"lon":2.25}},{"facility":"Research Site","city":"Bourges","country":"France","geoPoint":{"lat":47.08333,"lon":2.4}},{"facility":"Research Site","city":"Bron","country":"France","geoPoint":{"lat":45.73333,"lon":4.91667}},{"facility":"Research Site","city":"Chateauroux","country":"France","geoPoint":{"lat":46.81667,"lon":1.7}},{"facility":"Research Site","city":"Corbeil Essonnes Cedex","country":"France","geoPoint":{"lat":48.60603,"lon":2.48757}},{"facility":"Research Site","city":"Creteil","country":"France","geoPoint":{"lat":48.78333,"lon":2.46667}},{"facility":"Research Site","city":"Dijon","country":"France","geoPoint":{"lat":47.31667,"lon":5.01667}},{"facility":"Research Site","city":"LAGNY SUR MARNE cedex","country":"France","geoPoint":{"lat":48.86667,"lon":2.71667}},{"facility":"Research Site","city":"Le Chesnay","country":"France","geoPoint":{"lat":48.8222,"lon":2.12213}},{"facility":"Research Site","city":"Le Coudray","country":"France","geoPoint":{"lat":48.42115,"lon":1.50057}},{"facility":"Research Site","city":"Lyon Cedex 04","country":"France","geoPoint":{"lat":45.74848,"lon":4.84669}},{"facility":"Research Site","city":"Lyon","country":"France","geoPoint":{"lat":45.74848,"lon":4.84669}},{"facility":"Research Site","city":"MARSEILLE cedex 15","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"facility":"Research Site","city":"Marseille","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"facility":"Research Site","city":"Massy","country":"France","geoPoint":{"lat":48.72692,"lon":2.28301}},{"facility":"Research Site","city":"Melun","country":"France","geoPoint":{"lat":48.53333,"lon":2.66667}},{"facility":"Research Site","city":"Montauban","country":"France","geoPoint":{"lat":44.01667,"lon":1.35}},{"facility":"Research Site","city":"Montfermeil","country":"France","geoPoint":{"lat":48.8982,"lon":2.57913}},{"facility":"Research Site","city":"MONTREUIL Cedex","country":"France","geoPoint":{"lat":48.86415,"lon":2.44322}},{"facility":"Research Site","city":"Neuilly Sur Seine","country":"France","geoPoint":{"lat":48.8846,"lon":2.26965}},{"facility":"Research Site","city":"Nimes","country":"France","geoPoint":{"lat":43.83333,"lon":4.35}},{"facility":"Research Site","city":"Paris Cedex 13","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"PARIS Cedex 15","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"PESSAC Cedex","country":"France","geoPoint":{"lat":44.81011,"lon":-0.64129}},{"facility":"Research Site","city":"Quincy sous Sénart","country":"France","geoPoint":{"lat":48.67294,"lon":2.53419}},{"facility":"Research Site","city":"Rouen Cedex","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Research Site","city":"Strasbourg","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Research Site","city":"TOURS Cedex 9","country":"France","geoPoint":{"lat":47.38333,"lon":0.68333}},{"facility":"Research Site","city":"TOURS cedex","country":"France","geoPoint":{"lat":47.38333,"lon":0.68333}},{"facility":"Research Site","city":"VANNES cedex","country":"France","geoPoint":{"lat":47.66667,"lon":-2.75}},{"facility":"Research Site","city":"Bad Friedrichshall","country":"Germany"},{"facility":"Research Site","city":"Bad Nauheim","country":"Germany","geoPoint":{"lat":50.36463,"lon":8.73859}},{"facility":"Research Site","city":"Darmstadt","country":"Germany","geoPoint":{"lat":49.87167,"lon":8.65027}},{"facility":"Research Site","city":"Esslingen","country":"Germany","geoPoint":{"lat":48.73961,"lon":9.30473}},{"facility":"Research Site","city":"Freiburg","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"Research Site","city":"Gießen","country":"Germany","geoPoint":{"lat":50.58727,"lon":8.67554}},{"facility":"Research Site","city":"Hannover","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Research Site","city":"Ludwigshafen","country":"Germany","geoPoint":{"lat":49.48121,"lon":8.44641}},{"facility":"Research Site","city":"Lüdenscheid","country":"Germany","geoPoint":{"lat":51.21977,"lon":7.6273}},{"facility":"Research Site","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98419,"lon":8.2791}},{"facility":"Research Site","city":"Merseburg","country":"Germany","geoPoint":{"lat":51.35478,"lon":11.98923}},{"facility":"Research Site","city":"Wuppertal","country":"Germany","geoPoint":{"lat":51.27027,"lon":7.16755}},{"facility":"Research Site","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Research Site","city":"Debrecen","country":"Hungary","geoPoint":{"lat":47.53333,"lon":21.63333}},{"facility":"Research Site","city":"Pécs","country":"Hungary","geoPoint":{"lat":46.08333,"lon":18.23333}},{"facility":"Research Site","city":"Szeged","country":"Hungary","geoPoint":{"lat":46.253,"lon":20.14824}},{"facility":"Research Site","city":"Arezzo","country":"Italy","geoPoint":{"lat":43.46276,"lon":11.88068}},{"facility":"Research Site","city":"Ascoli Piceno","country":"Italy","geoPoint":{"lat":42.85351,"lon":13.57395}},{"facility":"Research Site","city":"Cona","country":"Italy","geoPoint":{"lat":44.80583,"lon":11.7069}},{"facility":"Research Site","city":"Forlì","country":"Italy","geoPoint":{"lat":44.22177,"lon":12.04144}},{"facility":"Research Site","city":"Genova","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94438}},{"facility":"Research Site","city":"Grosseto","country":"Italy","geoPoint":{"lat":42.76296,"lon":11.10941}},{"facility":"Research Site","city":"Massa","country":"Italy","geoPoint":{"lat":44.03541,"lon":10.13927}},{"facility":"Research Site","city":"Seriate","country":"Italy","geoPoint":{"lat":45.68532,"lon":9.72487}},{"facility":"Research Site","city":"Siena","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Research Site","city":"Alkmaar","country":"Netherlands","geoPoint":{"lat":52.63167,"lon":4.74861}},{"facility":"Research Site","city":"Arnhem","country":"Netherlands","geoPoint":{"lat":51.98,"lon":5.91111}},{"facility":"Research Site","city":"Den Bosch","country":"Netherlands","geoPoint":{"lat":51.27,"lon":5.59167}},{"facility":"Research Site","city":"Terneuzen","country":"Netherlands","geoPoint":{"lat":51.33583,"lon":3.82778}},{"facility":"Research Site","city":"A Coruña","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Research Site","city":"Alicante","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Research Site","city":"Badalona","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Research Site","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Hospitalet de Llobregat(Barcel","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Research Site","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Málaga","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Santiago(A Coruña)","country":"Spain"},{"facility":"Research Site","city":"Sevilla","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Vigo(Pontevedra)","country":"Spain"},{"facility":"Research Site","city":"Gävle","country":"Sweden","geoPoint":{"lat":60.67452,"lon":17.14174}},{"facility":"Research Site","city":"Linköping","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"facility":"Research Site","city":"Uppsala","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"facility":"Research Site","city":"Örebro","country":"Sweden","geoPoint":{"lat":59.27412,"lon":15.2066}},{"facility":"Research Site","city":"Ashford","country":"United Kingdom","geoPoint":{"lat":51.14648,"lon":0.87376}},{"facility":"Research Site","city":"Belfast","country":"United Kingdom","geoPoint":{"lat":54.59682,"lon":-5.92541}},{"facility":"Research Site","city":"Cambridge","country":"United Kingdom","geoPoint":{"lat":52.2,"lon":0.11667}},{"facility":"Research Site","city":"Coventry","country":"United Kingdom","geoPoint":{"lat":52.40656,"lon":-1.51217}},{"facility":"Research Site","city":"Eastbourne","country":"United Kingdom","geoPoint":{"lat":50.76871,"lon":0.28453}},{"facility":"Research Site","city":"Hastings","country":"United Kingdom","geoPoint":{"lat":50.85519,"lon":0.57292}},{"facility":"Research Site","city":"Middlesborough","country":"United Kingdom","geoPoint":{"lat":54.57623,"lon":-1.23483}},{"facility":"Research Site","city":"Newcastle-Upon-Tyne","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}},{"facility":"Research Site","city":"Norwich","country":"United Kingdom","geoPoint":{"lat":52.62783,"lon":1.29834}},{"facility":"Research Site","city":"Sheffield","country":"United Kingdom","geoPoint":{"lat":53.38297,"lon":-1.4659}}]},"referencesModule":{"references":[{"pmid":"25175921","type":"RESULT","citation":"Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014 Sep 11;371(11):1016-27. doi: 10.1056/NEJMoa1407024. Epub 2014 Sep 1."},{"pmid":"30353444","type":"DERIVED","citation":"Lapostolle F, Van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. Am J Cardiovasc Drugs. 2019 Apr;19(2):173-183. doi: 10.1007/s40256-018-0305-0."},{"pmid":"30302940","type":"DERIVED","citation":"Fabris E, Van't Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, Ten Berg JM, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Cantor WJ, Kerneis M, Diallo A, Vicaut E, Montalescot G; ATLANTIC investigators. Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):E369-E377. doi: 10.1002/ccd.27921. Epub 2018 Oct 9."},{"pmid":"29421015","type":"DERIVED","citation":"Bagai A, Goodman SG, Cantor WJ, Vicaut E, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Merkely B, Storey RF, Ten Berg JM, Zeymer U, Diallo A, Hamm CW, Tsatsaris A, El Khoury J, Van't Hof AW, Montalescot G. Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. Am Heart J. 2018 Feb;196:56-64. doi: 10.1016/j.ahj.2017.10.021. Epub 2017 Nov 4."},{"pmid":"29421001","type":"DERIVED","citation":"Kilic S, Fabris E, Van't Hof AWJ, Hamm CW, Lapostolle F, Lassen JF, Tsatsaris A, Diallo A, Vicaut E, Montalescot G; ATLANTIC Investigators. Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial. Am Heart J. 2018 Feb;196:1-8. doi: 10.1016/j.ahj.2017.09.018. Epub 2017 Oct 3."},{"pmid":"28939567","type":"DERIVED","citation":"Venetsanos D, Sederholm Lawesson S, Alfredsson J, Janzon M, Cequier A, Chettibi M, Goodman SG, Van't Hof AW, Montalescot G, Swahn E. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. BMJ Open. 2017 Sep 21;7(9):e015241. doi: 10.1136/bmjopen-2016-015241."},{"pmid":"28622941","type":"DERIVED","citation":"Cayla G, Lapostolle F, Ecollan P, Stibbe O, Benezet JF, Henry P, Hammett CJ, Lassen JF, Storey RF, Ten Berg JM, Hamm CW, Van't Hof AW, Montalescot G; ACTION study group. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. Int J Cardiol. 2017 Oct 1;244:49-53. doi: 10.1016/j.ijcard.2017.06.009. Epub 2017 Jun 9."},{"pmid":"27666002","type":"DERIVED","citation":"Lupi A, Schaffer A, Lazzero M, Tessitori M, De Martino L, Rognoni A, Bongo AS, Porto I. Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facility. Cardiovasc Revasc Med. 2016 Dec;17(8):528-534. doi: 10.1016/j.carrev.2016.08.005. Epub 2016 Aug 20."},{"pmid":"27196998","type":"DERIVED","citation":"Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW, Lapostolle F, Lassen JF, Collet JP, Ten Berg JM, Van't Hof AW, Montalescot G. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016 Aug 1;116(2):369-78. doi: 10.1160/TH15-12-0944. Epub 2015 May 19."},{"pmid":"26952907","type":"DERIVED","citation":"Montalescot G, van 't Hof AW, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Collet JP, Goodman SG, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Licour M, Merkely B, Salhi N, Silvain J, Storey RF, Ten Berg JM, Tsatsaris A, Zeymer U, Vicaut E, Hamm CW; ATLANTIC Investigators. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H(2)(4) Analysis. JACC Cardiovasc Interv. 2016 Apr 11;9(7):646-56. doi: 10.1016/j.jcin.2015.12.024. Epub 2016 Mar 5."},{"pmid":"23537967","type":"DERIVED","citation":"Montalescot G, Lassen JF, Hamm CW, Lapostolle F, Silvain J, ten Berg JM, Cantor WJ, Goodman SG, Licour M, Tsatsaris A, van't Hof AW. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J. 2013 Apr;165(4):515-22. doi: 10.1016/j.ahj.2012.12.015. Epub 2013 Feb 13."}],"seeAlsoLinks":[{"label":"D5130L00006_Protocol","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=482&filename=D5130L00006_Protocol_Redacted.pdf"},{"label":"D5130L00006_CSR_Synopsis","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=482&filename=D5130L00006_CSR_Synopsis.pdf"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Patients were randomized in pre-hospital settings at 102 Emergency Medical Services between September 2011 and October 2013. 1875 patients were recruited in the study, 1862 consented patients were randomized.","groups":[{"id":"FG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"FG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"based on randomized treatment","numSubjects":"909"},{"groupId":"FG001","comment":"based on randomized treatment","numSubjects":"953"}]},{"type":"Modified Intent to Treat Population","achievements":[{"groupId":"FG000","comment":"based on randomized treatment","numSubjects":"906"},{"groupId":"FG001","comment":"based on randomized treatment","numSubjects":"952"}]},{"type":"Safety Population","achievements":[{"groupId":"FG000","comment":"based on actual treatment","numSubjects":"908"},{"groupId":"FG001","comment":"based on actual treatment","numSubjects":"950"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"based on randomized treatment","numSubjects":"844"},{"groupId":"FG001","comment":"based on randomized treatment","numSubjects":"897"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"56"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Had other reason","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"6"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"BG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"909"},{"groupId":"BG001","value":"953"},{"groupId":"BG002","value":"1862"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"title":"Years","categories":[{"measurements":[{"groupId":"BG000","value":"60.6","spread":"12.38"},{"groupId":"BG001","value":"61.0","spread":"12.49"},{"groupId":"BG002","value":"60.8","spread":"12.43"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"196"},{"groupId":"BG002","value":"369"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"736"},{"groupId":"BG001","value":"757"},{"groupId":"BG002","value":"1493"}]}]}]},{"title":"Diabetes mellitus","paramType":"NUMBER","unitOfMeasure":"patients","classes":[{"title":"yes","categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"253"}]}]},{"title":"no/unknown","categories":[{"measurements":[{"groupId":"BG000","value":"794"},{"groupId":"BG001","value":"815"},{"groupId":"BG002","value":"1609"}]}]}]},{"title":"TIMI risk score","description":"Thrombolysis in Myocardial Infarction (TIMI) is a scoring system based on independant predictors of mortality such as age, diabetes mellitus, history of hypertension, history of angina, ST segment elevation. The death rate at 30 days for the following scores are: 0-2: 0.8%-2.2%, 3-6: 4.4% -16.1%, score\\>6: 23.4% to 35.9%.","paramType":"NUMBER","unitOfMeasure":"patients","classes":[{"title":"0-2","categories":[{"measurements":[{"groupId":"BG000","value":"552"},{"groupId":"BG001","value":"573"},{"groupId":"BG002","value":"1125"}]}]},{"title":"3-6","categories":[{"measurements":[{"groupId":"BG000","value":"337"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"702"}]}]},{"title":">6","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"35"}]}]}]},{"title":"Killip class","description":"Killip class assesses the presence and severity of heart failure by physical examination. Class I :No rales, no 3rd heart sound. Class 2: Rales in \\<1⁄2 lung field or presence of a 3rd heart sound. Class 3: Rales in \\>1⁄2 lung field-pulmonary edema.Class 4 : Cardiogenic shock-determined clinically.","paramType":"NUMBER","unitOfMeasure":"patients","classes":[{"title":"I","categories":[{"measurements":[{"groupId":"BG000","value":"819"},{"groupId":"BG001","value":"862"},{"groupId":"BG002","value":"1681"}]}]},{"title":"II, III, IV","categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"94"}]}]},{"title":"unknown","categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"87"}]}]}]},{"title":"First medical contact","paramType":"NUMBER","unitOfMeasure":"patients","classes":[{"title":"in ambulance","categories":[{"measurements":[{"groupId":"BG000","value":"689"},{"groupId":"BG001","value":"723"},{"groupId":"BG002","value":"1412"}]}]},{"title":"in emergency department","categories":[{"measurements":[{"groupId":"BG000","value":"220"},{"groupId":"BG001","value":"230"},{"groupId":"BG002","value":"450"}]}]}]},{"title":"PCI","description":"Percutaneous coronary intervention (PCI) is a non-surgery intervention performed to open blocked coronary arteries and to restore arterial blood flow to the heart tissue.","paramType":"NUMBER","unitOfMeasure":"Patients","classes":[{"title":"yes","categories":[{"measurements":[{"groupId":"BG000","value":"800"},{"groupId":"BG001","value":"830"},{"groupId":"BG002","value":"1630"}]}]},{"title":"no","categories":[{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"232"}]}]}]},{"title":"type of PCI","description":"on patients with PCI","paramType":"NUMBER","unitOfMeasure":"patients","classes":[{"title":"with stent","categories":[{"measurements":[{"groupId":"BG000","value":"760"},{"groupId":"BG001","value":"776"},{"groupId":"BG002","value":"1536"}]}]},{"title":"without stent","categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"94"}]}]}]},{"title":"Time between the 2 loading doses","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"minutes","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32","lowerLimit":"22","upperLimit":"45"},{"groupId":"BG001","value":"30","lowerLimit":"22","upperLimit":"43"},{"groupId":"BG002","value":"31","lowerLimit":"22","upperLimit":"44"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)","description":"(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.","populationDescription":"mITT, on patients with non missing values","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"At initial angiography, pre PCI","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"824"},{"groupId":"OG001","value":"856"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"145"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8214","pValueComment":"pvalue at 0.025 , adjusted for multiple comparisons","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.030","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.799","ciUpperLimit":"1.327"}]},{"type":"PRIMARY","title":"ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)","description":"ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\\<70%) resolution.","populationDescription":"mITT, on patients with non missing values","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"Between baseline and PCI","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"774"},{"groupId":"OG001","value":"824"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"102"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6322","pValueComment":"P value at 0.025 adjusted for multiple comparisons","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.074","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.801","ciUpperLimit":"1.441"}]},{"type":"SECONDARY","title":"1st Composite Clinical Endpoint","description":"death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death","populationDescription":"mITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"during the 30 days of treatment","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"906"},{"groupId":"OG001","value":"952"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9056","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.027","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.661","ciUpperLimit":"1.595"}]},{"type":"SECONDARY","title":"2nd Composite Clinical Endpoint","description":"Death/MI/urgent revascularization. Adjudicated events except death","populationDescription":"mITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"within 30 days of study","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"906"},{"groupId":"OG001","value":"952"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"34"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4168","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.215","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.760","ciUpperLimit":"1.942"}]},{"type":"SECONDARY","title":"Definite Stent Thrombosis","description":"Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint","populationDescription":"mITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"during 30 days of treatment","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"906"},{"groupId":"OG001","value":"952"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0307","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.189","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.042","ciUpperLimit":"0.856"}]},{"type":"SECONDARY","title":"TIMI Flow Grade 3 Post -PCI","description":"TIMI) flow grade 3 is complete perfusion post-PCI.","populationDescription":"mITT, on patients with non missing TIMI flow grade values","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"at coroangiography post-PCI","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"760"},{"groupId":"OG001","value":"784"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"625"},{"groupId":"OG001","value":"630"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.344","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.132","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.876","ciUpperLimit":"1.462"}]},{"type":"SECONDARY","title":"ST Segment Elevation Resolution Post-PCI >= 70%","description":"ST segment elevation resolution post PCI \\>=70% is defined as complete resolution","populationDescription":"mITT on patients with non missing ECG values","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"Between baseline and ECG 60 mn post-PCI","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"713"},{"groupId":"OG001","value":"743"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"390"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0547","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.225","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.996","ciUpperLimit":"1.506"}]},{"type":"SECONDARY","title":"Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI","description":"Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.","populationDescription":"mITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"during PCI","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"906"},{"groupId":"OG001","value":"952"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1660","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.803","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.588","ciUpperLimit":"1.096"}]},{"type":"SECONDARY","title":"Major Bleeds Within 48 Hours","description":"non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds","populationDescription":"Safety","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"within 48 hours of first dose","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"908"},{"groupId":"OG001","value":"950"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"}]}]}]},{"type":"SECONDARY","title":"Minor and Major Bleedings Within 48 Hours","description":"non CABG related bleeds (PLATO definition)","populationDescription":"Safety","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"within 48 hours of first dose","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"908"},{"groupId":"OG001","value":"950"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"}]}]}]},{"type":"SECONDARY","title":"Major Bleeds After 48 Hours","description":"non CABG related bleeds (PLATO definition) include life threatening and other major bleedings","populationDescription":"safety","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"after 48hours post-first dose","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"908"},{"groupId":"OG001","value":"950"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Minor and Major Bleeds After 48 Hours","description":"non CABG related bleeds (PLATO definition)","populationDescription":"safety","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"after 48 hours post first dose","groups":[{"id":"OG000","title":"Pre-hospital Ticagrelor","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."},{"id":"OG001","title":"In-hospital Ticagrelor","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"908"},{"groupId":"OG001","value":"950"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"16"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3.0","timeFrame":"within 30 days of study","description":"Actual Treatment Safety analysis set concerns 1858 patients - Ticagrelor pre-hosp:908 and Ticagrelor in-hosp: 950. 4 patients receiveived study medication not according to randomization assignment","eventGroups":[{"id":"EG000","title":"Ticagrelor In-Hosp","description":"Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.","seriousNumAffected":143,"seriousNumAtRisk":950,"otherNumAffected":529,"otherNumAtRisk":950},{"id":"EG001","title":"Ticagrelor Pre-Hosp","description":"Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.","seriousNumAffected":140,"seriousNumAtRisk":908,"otherNumAffected":469,"otherNumAtRisk":908}],"seriousEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"LEUKOCYTOSIS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ACUTE MYOCARDIAL INFARCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ANGINA PECTORIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":908}]},{"term":"ANGINA UNSTABLE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"AORTIC VALVE INCOMPETENCE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"ARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ARTERIOSPASM CORONARY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"ATRIAL FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":908}]},{"term":"ATRIOVENTRICULAR BLOCK COMPLETE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"BRADYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"CARDIAC ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":950},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":908}]},{"term":"CARDIAC ASTHMA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CARDIAC FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":950},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":908}]},{"term":"CARDIAC FAILURE ACUTE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"CARDIAC TAMPONADE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"CARDIOGENIC SHOCK","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":950},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":908}]},{"term":"CARDIOPULMONARY FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"CONGESTIVE CARDIOMYOPATHY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CORONARY ARTERY OCCLUSION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"DRESSLER'S SYNDROME","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"INTERVENTRICULAR SEPTUM RUPTURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"INTRACARDIAC THROMBUS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"LEFT VENTRICULAR DYSFUNCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"LEFT VENTRICULAR FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"MYOCARDIAL RUPTURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PALPITATIONS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"PERICARDIAL EFFUSION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"PERICARDITIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"TORSADE DE POINTES","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"VENTRICLE RUPTURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"VENTRICULAR EXTRASYSTOLES","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"VENTRICULAR FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":30,"numAtRisk":950},{"groupId":"EG001","numEvents":23,"numAffected":23,"numAtRisk":908}]},{"term":"VENTRICULAR SEPTAL DEFECT ACQUIRED","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"VENTRICULAR TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":950},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":908}]},{"term":"VENTRICULAR SEPTAL DEFECT","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"VERTIGO","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"COLITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"COLITIS ISCHAEMIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"GASTRIC ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"GASTRIC ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"GASTRITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"GASTROINTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"GASTROINTESTINAL TELANGIECTASIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HAEMATEMESIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HAEMATOCHEZIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"INTESTINAL ISCHAEMIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"MELAENA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"RECTAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"RETROPERITONEAL HAEMATOMA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"CARDIAC DEATH","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"DEVICE MALFUNCTION","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"MULTI-ORGAN FAILURE","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"NON-CARDIAC CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":908}]},{"term":"SUDDEN CARDIAC DEATH","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"SUDDEN DEATH","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"THROMBOSIS IN DEVICE","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"VESSEL PUNCTURE SITE HAEMATOMA","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"BILIARY COLIC","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CHOLECYSTITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CHOLECYSTITIS ACUTE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"BILIARY SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"BRONCHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"GASTROENTERITIS VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"GROIN INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"LUNG INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"RELAPSING FEVER","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"SEPTIC SHOCK","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"SKIN INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"UROSEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"FEMORAL NECK FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"POST PROCEDURAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"POST PROCEDURAL HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PROCEDURAL HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":908}]},{"term":"SUBDURAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"TRAUMATIC HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"UPPER LIMB FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"VASCULAR PSEUDOANEURYSM","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"HAEMOGLOBIN DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"HEPATIC ENZYME INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"NUTRITIONAL CONDITION ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PLATELET COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"TROPONIN INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"DEHYDRATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"MUSCULOSKELETAL CHEST PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"PAIN IN JAW","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"PATHOLOGICAL FRACTURE","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ADRENAL ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"BLADDER NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CARDIAC MYXOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"RECTAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"RENAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"CEREBRAL HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CEREBROVASCULAR ACCIDENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"DYSARTHRIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"HAEMORRHAGE INTRACRANIAL","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HEMIPARESIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"LACUNAR INFARCTION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PRESYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"SYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"TRANSIENT ISCHAEMIC ATTACK","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ANXIETY","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CONFUSIONAL STATE","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"SUICIDE ATTEMPT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HAEMATURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"RENAL COLIC","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"RENAL FAILURE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"RENAL FAILURE ACUTE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"ACUTE PULMONARY OEDEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":950},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":908}]},{"term":"ACUTE RESPIRATORY DISTRESS SYNDROME","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ATELECTASIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"DIAPHRAGMATIC PARALYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"HAEMOTHORAX","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"LUNG DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PLEURAL EFFUSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PULMONARY EMBOLISM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"PULMONARY OEDEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":908}]},{"term":"RESPIRATORY DISTRESS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"RASH PRURITIC","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"AORTIC DISSECTION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":908}]},{"term":"ARTERY DISSECTION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"HAEMATOMA","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HAEMODYNAMIC INSTABILITY","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]},{"term":"ORTHOSTATIC HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":950},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":908}]},{"term":"THROMBOPHLEBITIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":950},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":908}]}],"otherEvents":[{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":81,"numAtRisk":950},{"groupId":"EG001","numAffected":79,"numAtRisk":908}]},{"term":"Dyspnoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":86,"numAtRisk":950},{"groupId":"EG001","numAffected":62,"numAtRisk":908}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":950},{"groupId":"EG001","numAffected":41,"numAtRisk":908}]},{"term":"Non cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":950},{"groupId":"EG001","numAffected":42,"numAtRisk":908}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":950},{"groupId":"EG001","numAffected":44,"numAtRisk":908}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":950},{"groupId":"EG001","numAffected":28,"numAtRisk":908}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":950},{"groupId":"EG001","numAffected":19,"numAtRisk":908}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":950},{"groupId":"EG001","numAffected":34,"numAtRisk":908}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":950},{"groupId":"EG001","numAffected":30,"numAtRisk":908}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":950},{"groupId":"EG001","numAffected":32,"numAtRisk":908}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":950},{"groupId":"EG001","numAffected":30,"numAtRisk":908}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":950},{"groupId":"EG001","numAffected":28,"numAtRisk":908}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"This urgent setting study included 8.6% of patients with symptoms of MI in ambulance but having finally not a STEMI diagnosis in cathlab.\n\nNo prespecified hypothesis and procedure for adjustment was made on secondary endpoints."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Dr Tomas Andersson MD","organization":"AstraZeneca","email":"tomas.lg.andersson@astrazeneca.com","phone":"00 46 31 77 61966"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Israel"]},"conditionBrowseModule":{"meshes":[{"id":"D000009203","term":"Myocardial Infarction"},{"id":"D000072657","term":"ST Elevation Myocardial Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11845","name":"Myocardial Infarction","asFound":"Myocardial Infarction","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M1072","name":"ST Elevation Myocardial Infarction","asFound":"STEMI","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077486","term":"Ticagrelor"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1812","name":"Ticagrelor","asFound":"DNA","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}